FISCAL YEAR 2023, STRATEGIC TRANSFORMATION OF THE GROUP Continued total year growth in core business revenues, up 39%Successful deployment of the Group s strategy: Proprietary products up at 30% of.
OSE Immunotherapeutics announces a collaboration agreement with GenDx to develop and validate a companion diagnostic test in preparation for the confirmatory pivotal Phase 3 clinical trial of.
ACCELERATION OF STRATEGIC DEPLOYMENT IN THE FIRST HALF OF 2023 Strong growth in half-year core business revenues, up 37%Successful deployment of the Group s strategy: Share of proprietary products.
EUROBIO : ACCELERATION OF STRATEGIC DEPLOYMENT IN THE FIRST HALF OF 2023 finanzen.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.ch Daily Mail and Mail on Sunday newspapers.
EUROBIO : ACCELERATION OF STRATEGIC DEPLOYMENT IN THE FIRST HALF OF 2023 itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.